Jeffrey K. Merk – Aird Berlis

Jeffrey is co-Practice Group Leader of the firm’s Capital Markets Group and co-Chair of the Life Sciences Group. He is also a member of the firm’s Corporate/Commercial, Mergers & Acquisitions/Private Equity and International Groups, as well as the Cannabis and Mines & Minerals Groups. He practises corporate law with an emphasis on public and private financings, mergers and acquisitions, corporate governance and ongoing general corporate and commercial activities. Jeffrey’s experience includes numerous cross-border securities offerings (public and private), acting for U.S. buyers of Canadian entities or assets; acting for U.S. financiers of acquisitions in Canada; acting for Canadian sellers to U.S. buyers, and acting as Canadian counsel in connection with large, internationally-led transactions. He frequently advises mining, private equity, industrial, cannabis and psychedelics clients.Jeffrey has recently been featured in the media with respect to the legal, regulatory and investment context for psychedelics in Canada.

Jeffrey offers clients a practical and business-minded approach to solving legal and regulatory challenges, and has been recommended in The Legal 500 Canada for his expertise in the practice area of Corporate and M&A. He is skilled at isolating what is truly important in a complex business transaction and in identifying solutions. Jeffrey takes great care in tailoring his service to each client and providing strategic and insightful judgment to effectively further their business objectives.

Matters

• Represented AltMed Capital Corp., a leading Canadian ketamine clinic operator, psychedelic medicine IP aggregator and novel drug discoverer, in connection with:
  • Various aspects of its operations, including licensing matters, employment matters, tax structuring, joint ventures, services and leasing arrangements and intellectual property commercialization.
  • The sale of 100% of its issued and outstanding shares to Champignon Brands Inc., a company specializing in the formulation of a suite of medicinal mushrooms health products, as well as novel ketamine, anaesthetics and adaptogenic delivery platforms for the nutritional, wellness and alternative medicine industries.
  • Its acquisition of the Canadian Rapid Treatment Centre of Excellence Inc., a Canadian intravenous ketamine infusion therapy clinic.

Socials

• LinkedIn